Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | LTA4H | P09960 | 5/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511532 | 1.00 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL2324766 | 0.90 | MEN1 (0.57) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL28517201 | 0.89 | CYP1A2 (0.61) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL31641747 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL15016523 | 0.83 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL15567163 | 0.77 | LTA4H (0.60) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL1964818 | 0.77 | KDM4E (0.66) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL954152 | 0.77 | KDM4E (0.70) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL14784605 | 0.77 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ALMNAKDM4E | |
| SCHEMBL24398580 | 0.76 | LTA4H (0.59) | ALDH1A1MEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | ALDH1A1 1084/4885MEN1 3568/4885KMT2A 4813/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ALDH1A1 1084/4885MEN1 3568/4885KMT2A 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.